Join us on Thursday, April 13^th for this CME/MOC-accredited webinar
5:00 PM – 6:00 PM ET

Thursday, April 13, 2023
5:00 PM – 6:00 PM ET
Live CME/MOC-accredited webinar

Topics to Be Discussed

• Module 1: Management of Metastatic Non-Small Cell Lung Cancer (NSCLC) without an Actionable Mutation
• Module 2: Advances in the Care of Patients with Nonmetastatic NSCLC and Small Cell Lung Cancer

Target Audience
This program is intended for medical and radiation oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of lung cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

• Evaluate available and emerging data documenting the efficacy and safety of anti-PD-1/PD-L1 antibody-based approaches as neoadjuvant or adjuvant therapy for patients with nonmetastatic non-small cell lung cancer (NSCLC).
• Appraise the FDA approval of anti-PD-L1 antibody consolidation therapy for patients with unresectable Stage III NSCLC who have not experienced disease progression after standard platinum-based chemotherapy concurrent with radiation therapy, and appropriately integrate this strategy into routine clinical practice.
• Review recent therapeutic advances related to the use of anti-PD-1/PD-L1 antibodies as monotherapy or in combination with chemotherapy, chemobiologic therapy or anti-CTLA-4 antibodies for metastatic NSCLC, and discern how these approaches can be optimally employed in the management of this disease.
• Develop a long-term care plan for patients with progressive NSCLC, considering exposure to prior systemic therapy, symptomatology, performance status and personal goals of treatment.
• Appreciate available clinical trial findings informing the use of immune checkpoint inhibitors in combination with platinum-based chemotherapy for patients with previously untreated extensive-stage small cell lung cancer (SCLC).
• Design an optimal approach to the clinical care of patients with progressive SCLC, considering the implications of prior therapeutic exposure, symptomatology and other factors.
• Recall new data with agents and strategies currently under investigation for lung cancer without actionable mutations, and consider the potential roles of these approaches and ongoing trial opportunities for eligible patients.

CE Credit
CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Paz-Ares — Advisory Committee: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Eisai Inc, EMD Serono Inc, Genentech, a member of the Roche Group, GSK, Guardant Health, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Merck Sharp & Dohme LLC, Novartis, Pfizer Inc, PharmaMar, Regeneron Pharmaceuticals Inc, Sanofi, Takeda Pharmaceuticals USA Inc: Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Pfizer Inc, PharmaMar; Nonrelevant Financial Relationship: Altum Sequencing (stock options/ownership). Dr Wakelee — Advisory Committee (Uncompensated): Genentech, a member of the Roche Group, Merck; Contracted Research: ACEA Biosciences Inc, Arrys Therapeutics, a wholly owned subsidiary of Kyn Therapeutics, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Clovis Oncology, Genentech, a member of the Roche Group, Helsinn Healthcare SA, Merck, Novartis, Seagen Inc, Xcovery; Data and Safety Monitoring Board/Committee: Mirati Therapeutics Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Merck, Novocure Inc, and Sanofi.